BRAF and neoplasm: This envisions a synergistic use of ctDNA tracking and NGS analysis under the guidance of the BRAF-mutant ctDNA absolute amount, which appears more accurate in defining the tumor burden and more reliable in comparing different time points being unaffected by external influences.